A new molecule would slow cognitive decline in the early stages of the disease
Should we rejoice in the new treatment validated by the American Medicines Agency (FDA)? It is still too early to claim victory. And yet, this new molecule against Alzheimer’s, aimed at reducing the cognitive decline of patients suffering from this neurodegenerative disease, is eagerly awaited after the failed launch of a previous drug with a similar mechanism a year and a half ago. The new treatment, which will be marketed by the pharmaceutical company Eisai under the name Leqembi, is now recommended for patients who have not yet reached an advanced stage of the disease. It represents ‘an important step forward in our battle to tr
Related posts:
an increase is expected in the next two weeks
Here are the 11 risk factors for dementia according to a study
Max Verstappen "Decision to soft start with Reconosans lap" / F1 Hungarian GP Final[F1-Gate.com]
Muggle Quidditch, zorbing... Unusual sports to try to get out of the routine
cases of monkeypox triple in two weeks in Europe
OM – The Tudor method deciphered by its former players
Yuan Yue's Magical Journey: From Winning Streak to Facing Gauff - A Reflection on Confidence and Sel...
European Championships: Beach Volleyball: Surprising duel in the final